Biologika in der pädiatrischen Allergologie

Zusammenfassung

Gegenwärtige therapeutische Strategien beim Asthma bronchiale stützen sich im Wesentlichen auf symptomatische Therapieformen. Diese Zusammenfassung zeigt, welche Erfolge von neueren und pathogenetisch orientierten Therapieformen zu erwarten ist. Im Besonderen werden Funktionsweisen und klinische Daten zu Anti-IgE und Anti-IL-5 vorgestellt. Anti-IgE ist bereits bei Kindern ab dem 6. Lebensjahr für die subkutane Applikation zugelassen. Dagegen ist die Anwendung des intravenös zu verabreichenden monoklonalen Anti-IL-5 aktuell nur im Rahmen von klinischen Studien möglich.

Summary

Current therapeutic strategies fort the control of bronchial asthma are mainly based on pure symptomatic approaches. This review tries to shed some light on modern pathogenesis oriented strategies including anti-IgE and anti-IL-5. Mechanisms of function as well as clinical data will be presented. While anti-IgE is already approved for the subcutaneous treatment of severe bronchial asthma in children from the age of 6, intravenous anti-IL-5 is currently only available in clinical trials.

Schlüsselwörter

Anti-IgE - Anti-IL-5 - Omalizumab - Mepolizumab - Hypereosinophilie

Keywords

Anti-IgE - anti-IL-5 - omalizumab - mepolizumab - hypereosinophilia

• Literatur

• 1 Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma.. Cochrane Database Syst Rev 2003; (04) CD001186
• 2 Alton EW. et al Asthma prophylaxis agents alter the function of an airway epithelial chloride channel.. Am J Respir Cell Mol Biol 1996; 14: 380-387.
• 3 Burrows B. et al Association of asthma with serum IgE levels and skin-test reactivity to allergens.. N Engl J Med 1989; 320: 271
• 4 Rajakulasingam K. et al Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) alpha chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells.. J Allergy Clin Imunol 1997; 100: 78-86.
• 5 Rajakulasingam K. et al Increased expression of high affinity IgE (FcepsilonRI) receptor-alpha chain mRNA and protein-bearing eosinophils in human allergen-induced atopic asthma.. Am J Respir Crit Care Med 1998; 158: 233-240.
• 6 Foster B, Metcalfe DD, Prussin D. Human dendritic cell 1 and dendritic cell 2 subsets express Fcepsilon- RI: correlation with serum IgE and allergic asthma.. J Allergy Clin Immunol 2003; 112: 1132-1138.
• 7 Holloway JA, Holgate ST, Semper AE. Expression of the high-affinity IgE receptor on peripheral blood dendritic cells: differential binding of IgE in atopic asthma.. J Allergy Clin Immunol 2001; 107: 1009-1018.
• 8 Babu KS, Arshad SH, Holgate ST. Omalizumab, a novel anti-IgE therapy in allergic disorders.. Expert Opin Biol Ther 2001; 1: 1049-1058.
• 9 Prussin C. et al Omalizumab treatment downregulates dendritic cell FcepsilonRI expression.. J Allergy Clin Immunol 2003; 112: 1147-1154.
• 10 MacGlashan Jr DW. et al Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.. J Immunol 1997; 158: 1438-1445.
• 11 Hamelmann E, Wahn U. Anti-IgE therapy.. Clin Allergy Immunol 2008; 21: 415-427.
• 12 Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.. Clin Pharmacokinet 2011; 50: 215-227.
• 13 Garrett JK. et al Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.. J Allergy Clin Immunol 2004; 113: 115-119.
• 14 Humbert M. et al Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.. Allergy 2005; 60: 309-316.
• 15 Milgrom H. et al Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).. Pediatrics 2001; 108: E36
• 16 Hart TK. et al Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.. J Allergy Clin Immunol 2001; 108: 250-257.
• 17 Holgate ST. et al Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.. Clin Exp Allergy 2005; 35: 408-416.
• 18 Gleich GJ, Leiferman KM. The hypereosinophilic syndromes: current concepts and treatments.. Br J Haematol 2009; 145: 271-285.
• 19 Nair P. et al Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.. N Engl J Med 2009; 360: 985-993.
• 20 Gevaert P. et al Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.. J Allergy Clin Immunol 2006; 118: 1133-1141.
• 21 Rothenberg ME. et al Treatment of patients with the hypereosinophilic syndrome with mepolizumab.. N Engl J Med 2008; 358: 1215-1228.
• 22 Walsh GM. Mepolizumab and eosinophil-mediated disease.. Curr Med Chem 2009; 16: 4774-4778.
• 23 Kim S. et al Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.. J Allergy Clin Immunol 2010; 125: 1336-1343.
• 24 Straumann A. et al Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.. Gut 2010; 59: 21-30.
• 25 Oldhoff JM. et al Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.. Allergy 2005; 60: 693-696.
• 26 Phipps S. et al Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin.. J Invest Dermatol 2004; 122: 1406-1412.
• 27 Chusid MJ. et al The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.. Medicine 1975; 54: 1-27.
• 28 American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions.. Am J Respir Crit Care Med 2000; (162) 2341-2351.
• 29 Haldar P. et al Mepolizumab and exacerbations of refractory eosinophilic asthma.. N Engl J Med 2009; 360: 973-984.